Galy

Thesis

Galy (lab-grown cotton) closed a $33M Series B led by Breakthrough Energy Ventures and has a $50M, 10-year offtake agreement with Suzuran Medical. Sam Altman and Tim Draper are on the cap table. The company is developing cellular agriculture for cotton. Growing cotton fibers in bioreactors rather than in fields. The cotton market is massive (~$50B annually) and environmentally destructive. Cotton farming uses enormous amounts of water and pesticides. Lab-grown cotton could fundamentally disrupt this supply chain if it can achieve cost parity. The $50M offtake agreement with Suzuran Medical provides revenue visibility and commercial validation. The investor roster is impressive. Breakthrough Energy Ventures (Bill Gates), Sam Altman, and Tim Draper all have track records of backing transformative technology. The $33M Series B provides runway for the next development phase. Retail access is available through Agronomics Ltd (LSE: ANIC), a listed fund holding shares in Galy and other cellular agriculture companies. This is the simplest retail exposure to lab-grown materials.

Catalysts

• +$50M 10-year offtake agreement with Suzuran Medical provides revenue visibility
• +Breakthrough Energy Ventures lead investor with Sam Altman and Tim Draper on cap table
• +Indirect retail exposure available through Agronomics Ltd (LSE: ANIC)

Risks

• -Lab-grown cotton has not yet achieved cost parity with field-grown cotton
• -Cellular agriculture for materials has a poor track record. Bolt Threads failed
• -Small Series B ($33M) may be insufficient for manufacturing scale-up

Common questions